ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

SABS SAB Biotherapeutics Inc

4,03
0,01 (0,25%)
03 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
SAB Biotherapeutics Inc SABS NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,01 0,25% 4,03 23:16:11
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
4,00 4,00 4,1002 4,03 4,02
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
16.4.202413:15GLOBESAB Biotherapeutics Provides SAB-142 Trial Update
08.4.202413:15GLOBESAB Biotherapeutics to Present at INNODIA Annual Meeting
04.4.202413:15GLOBESAB Biotherapeutics to Present at the Needham Virtual..
29.3.202412:15GLOBESAB Biotherapeutics Reports Full Year 2023 Operating and..
25.3.202415:15GLOBESAB Biotherapeutics Announces Clinical Partnership with..
08.3.202422:30EDGAR2Form 8-K - Current report
23.2.202422:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.2.202422:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.2.202414:00GLOBESAB Biotherapeutics to Present at the BIO CEO & Investor..
08.2.202414:00GLOBESAB Biotherapeutics to Present at the Oppenheimer..
02.2.202413:53EDGAR2Form 8-K - Current report
02.2.202413:30GLOBESAB Biotherapeutics Announces Executive Leadership Change
26.1.202422:15EDGAR2Form 8-K - Current report
26.1.202422:00EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
25.1.202423:00EDGAR2Form 8-K - Current report
23.1.202423:58GLOBESAB Biotherapeutics Regains Compliance with Nasdaq Minimum..
19.1.202422:21EDGAR2Form 8-K - Current report
03.1.202415:00EDGAR2Form 8-K - Current report
02.1.202422:30GLOBESAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
18.12.202315:34EDGAR2Form DEF 14A - Other definitive proxy statements
08.12.202323:26EDGAR2Form PRE 14A - Other preliminary proxy statements
30.11.202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.11.202313:40EDGAR2Form 8-K - Current report
29.11.202313:30GLOBESAB Biotherapeutics Announces Commencement of the HUMAN..
29.11.202306:15EDGAR2Form EFFECT - Notice of Effectiveness
28.11.202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28.11.202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.11.202322:45EDGAR2Form 8-K - Current report
20.11.202323:00EDGAR2Form 8-K - Current report
20.11.202322:45EDGAR2Form S-3/A - Registration statement under Securities Act of..
20.11.202313:30GLOBESAB Biotherapeutics Appoints Katie Ellias to the Board of..
15.11.202301:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.11.202313:30GLOBESAB Biotherapeutics Announces Completion of $67.1 Million..
14.11.202313:15GLOBESAB Biotherapeutics Announces Q3 2023 Financial Results and..
13.11.202322:48EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09.11.202313:30GLOBESAB Biotherapeutics to Present at Piper Sandler Healthcare..
03.11.202322:00EDGAR2Form S-3 - Registration statement under Securities Act of..
03.11.202321:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30.10.202322:00EDGAR2Form DEF 14A - Other definitive proxy statements
27.10.202323:00EDGAR2Form 8-K - Current report
24.10.202323:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.10.202313:30GLOBESAB Biotherapeutics Appoints Michael G. King Jr. as Chief..
20.10.202322:30EDGAR2Form PRE 14A - Other preliminary proxy statements
19.10.202313:30GLOBESAB Biotherapeutics Receives Australian Approval to Commence..
05.10.202313:30GLOBESAB Biotherapeutics Approves Appointment of Andrew Moin to..
02.10.202322:10EDGAR2Form 8-K - Current report
02.10.202313:30GLOBESAB Biotherapeutics Announces Private Placement of up to..
21.8.202322:15EDGAR2Form S-3 - Registration statement under Securities Act of..
21.8.202314:30GLOBESAB Biotherapeutics Provides Company Update for Q2..
21.8.202314:25EDGAR2Form 8-K - Current report

Kürzlich von Ihnen besucht

Delayed Upgrade Clock